Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.

Margherita RiminiCarles Fabregat-FrancoMara PersanoValentina BurgioFrancesca BergamoMonica NigerMario ScartozziIlario Giovanni RapposelliGiuseppe AprileFrancesca RattiFederica PedicaHelena VerdaguerMario RizzatoFederico NichettiEleonora LaiAlessandro CappettaTeresa MacarullaMatteo FassanFilippo De BraudAndrea PrettaFrancesca SimionatoFrancesco De CobelliLuca AldrighettiLorenzo FornaroStefano CascinuAndrea Casadei-Gardini

Published in: Targeted oncology (2023)

The present analysis constitutes the first evidence of a negative prognostic impact of IDH1 mutations in a cohort of patients treated after progression on first-line therapies in contrast to IDH1 inhibitors.

Keyphrases

wild type
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
magnetic resonance
peritoneal dialysis
patient reported outcomes
computed tomography
magnetic resonance imaging